Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
stock market
Biotech
BridgeBio fears biotech markets may stay 'pretty bad' until 2024
BridgeBio's recent cost-cutting measures reflect a belief that markets could “stay pretty bad up until the end of next year”.
Nick Paul Taylor
May 24, 2022 8:37am
Ginkgo bowled over as short seller dubs it 'a hoax for the ages'
Oct 6, 2021 3:03pm
Cassava CEO blames short sellers for data woes
Sep 3, 2021 8:28am
BioCryst scraps $200M offering after seeing share price slide
Aug 11, 2021 7:35am
Denali's Hunter syndrome data fail to impress
Jul 26, 2021 12:38pm
Seres Therapeutics' microbiome therapy flops against placebo
Jul 22, 2021 7:30am
